| [1] |
张念华. CXCR4和CD133共表达对II-III期结肠癌预后影响的分析[D]. 广州:南方医科大学, 2012.
|
| [2] |
程继荣，王淑琴，祖木热提, 等. 肺癌组织中CD133和CD105的表达及其临床意义[J]. 癌症, 2010, 30(4):334-337.
|
| [3] |
李小卫，姚宝忠，李展宇, 等. CD133、β-catenin在胰腺癌中的表达及其临床关联性[J/CD]. 中华普通外科学文献(电子版), 2011, 5(2):115-119.
|
| [4] |
Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage non-small cell lung cancer[J]. J Pathol, 2003, 200(5):620-626.
|
| [5] |
霍胜军，汤恢焕，魏伟. CXCL12及受体CXCR4在胆管癌中的表达及其临床意义[J]. 现代生物医学进展, 2008, 8(4):658-660.
|
| [6] |
Matsumoto K, Shariat SF, Ayala GE, et al. Loss of coxsackie and adenovirus receptor expression is associated with features of aggressive bladder cancer[J]. Urology, 2005, 66(2):441-446.
|
| [7] |
Maeda S, Shinchi H, Kurahara H, et al. CD133 expression is correlated with lymph node metastasis and vascular endothelial growth factor-C expression in pancreatic cancer[J]. Br J Cancer, 2008, 98(8):1389-1397.
|
| [8] |
Kohga K, Tatsumi T, Takehara T, et al. Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma[J]. J Hepatol, 2010, 52(6):872-879.
|
| [9] |
Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells[J]. Cancer Res, 2007, 67(3):1030-1037.
|
| [10] |
Hermann PC, Huber SL, Herrler T, et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer[J]. Cell Stem Cell, 2007, 1(3):313-323.
|
| [11] |
Moriyama T, Ohuchida K, Mizumoto K, et al. Enhanced cell migration and invasion of CD133+ pancreatic cancer cells cocultured with pancreatic stromal cells[J]. Cancer, 2010, 16(14):3357-3368.
|
| [12] |
Li X, Zhao H, Gu J, et al. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis[J]. Int J Clin Exp Pathol, 2015, 8(10):12084-12092.
|
| [13] |
Tsukasa K, Ding Q, Miyazaki Y, et al. miR-30 family promotes migratory and invasive abilities in CD133(+) pancreatic cancer stem-like cells[J]. Hum Cell, 2016, 29(3):130-137.
|
| [14] |
Xin B, He X, Wang J, et al. Nerve growth factor regulates CD133 function to promote tumor cell migration and invasion via activating ERK1/2 signaling inpancreatic cancer[J]. Pancreatology, 2016, 16(6):1005-1014.
|
| [15] |
Mizukami T, Kamachi H, Mitsuhashi T, et al. Immunohistochemical analysis of cancer stem cell markers in pancreatic adenocarcinoma patients after neoadjuvant chemoradiotherapy[J]. BMC Cancer, 2014, 14:687.
|
| [16] |
喻亚群，陈谦. 趋化因子CXCL12及受体CXCR4与肿瘤的发生及转移[J/CD]. 中华普通外科学文献(电子版), 2010, 4(2):155-157.
|
| [17] |
Koshiba T, Hosotani R, Miyamoto Y, et al. Expression of stromal cell-derived factor 1 and CXCR4 ligand receptor system in pancreatic cancer: a possible role for tumor progression[J]. Clin Cancer Res, 2000, 6(9):3530-3535.
|
| [18] |
Marchal R, Demetter P, Nagy N, et al. High expression of CXCR4 may predict poor survival in resected pancreatic adenocarcinoma[J]. Br J Cancer, 2009, 100(9):1444-1451.
|
| [19] |
Krieg A, Riemer JC, Telan LA, et al. CXCR4--A prognostic and clinicopathological biomarker for pancreatic ductal adenocarcinoma: a Meta-analysis[J]. PLoS ONE, 2015, 10(6):e0130192.
|
| [20] |
Wu H, Zhu L, Zhang H, et al. Coexpression of EGFR and CXCR4 predicts poor prognosis in resected pancreatic ductal adenocarcinoma[J]. PLoS ONE, 2015, 10(2):e0116803.
|
| [21] |
Zhao HL, Guo LY, Zhao H, et al. CXCR4 over-expression and survival in cancer: a system review and meta-analysis[J]. Oncotarget, 2015, 6(7):5022-5040.
|
| [22] |
费立明，王长亮，赵文华, 等. CXCL12及其受体CXCR4在胰腺癌中的表达及其与淋巴管生成的相关性[J]. 中华外科杂志, 2009, 47(10):783-786.
|
| [23] |
Singh S, Srivastava SK, Bhardwaj A, et al. CXCL12-CXCR4 signalling axis confers gemcitabinae resistance to pancreatic cancer cells: a novel target for therapy[J]. Br J Cancer, 2010, 103(11):1671-1679.
|
| [24] |
Zhang H, Wu HW, Guan J, et al. Paracrine SDF-1α signaling mediates the effects of PSCs on GEM chemoresistance through an IL-6 autocrine loop in pancreatic cancer cells[J]. Oncotarget, 2015, 6(7):3085-3097.
|